Stock NBIX NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
142.3 USD +0.27% Intraday chart for Neurocrine Biosciences, Inc. +4.09% +7.99%
May. 16 Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing MT
May. 14 Transcript : Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing
MT
Transcript : Neurocrine Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
PR
Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
CI
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
AQ
Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
CI
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
PR
Neurocrine Biosciences starts Phase one first-in-human clinical study of NBI-1117567
AQ
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
PR
Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
CI
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
PR
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
PR
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst? Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
CI
Neurocrine Biosciences Presented CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024
AQ
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
PR
Neurocrine Biosciences Presents CAHtalyst Pediatric Study Baseline Characteristics and CAHtalog Registry Data at PES 2024
CI
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating
MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating
MT
Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell
MT
Transcript : Neurocrine Biosciences, Inc., Q1 2024 Earnings Call, May 01, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. News Neurocrine Biosciences, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW